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CHAPTER 1. INTRODUCTION 
Salmonella spp. have been recognized as one of the most common causes of 
bacterial foodbome illnesses in humans (6, 8, 18, 22, 115, 140, 142, 159, 160). Salmonella 
spp. are responsible for an estimated 1.4 million cases of foodbome illnesses and 600 
deaths each year in the United States alone (115, 144, 168). Salmonella infection in 
humans currently ranks as the most costly bacterial foodbome illness due to medical 
expense and productivity losses (28, 31, 37, 54, 84, 115). 
Salmonella infection in humans can be acquired from various sources because the 
pathogen is commonly found in nature (8, 23, 24, 132, 142). However, most cases of 
human salmonellosis result from the ingestion of contaminated food products of animal 
origin, such as poultry, eggs, beef, pork, unpasteurized dairy products, and sea food (18, 31, 
54, 159, 161, 173). This is because food animals are primary reservoirs for Salmonella spp. 
(23, 24, 81, 140, 142, 167). Like other food products of animal origin, pork products 
significantly contribute to Salmonella infection in humans (29, 66, 126, 158). 
Distribution of Salmonella spp. on swine farms is relatively widespread in the 
United States (8, 47, 53, 132). A significant proportion of healthy pigs have also been 
found to be carriers of Salmonella spp. (21, 177). Additionally, numerous studies have 
reported that Salmonella prevalence in the majority of market hogs frequently increases 
after transportation and/or during lairage before slaughter, as compared to the rates 
measured on the farm (35, 56, 65, 75, 118, 158, 177, 178). As with other animals, swine 
that are infected or are carriers at the last stage of pig production are likely to be sources for 
direct or indirect rapid dissemination of Salmonella spp. into uninfected pigs immediately 
before slaughter (21, 24, 56, 65, 75, 76, 125, 157, 158). Realistically, this type of 
transmission seems unavoidable. Some experimental studies supported the fact that 
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Salmonella enterica serovar Typhimurium is able to acutely infect pigs (51, 74). These 
studies showed that Salmonella serovar Typhimurium could spread into the tissues of 
animals within a few hours after an initial challenge (51, 74). Thus, the acute acquisition of 
Salmonella spp. immediately prior to slaughter is believed to be an important risk factor in 
swine because it could cause carcass contamination during the slaughter process. 
Eventually this would become a source of Salmonella spp. for foodborne illness among 
consumers (8, 24, 35, 56, 74-77, 157, 176). 
Also of concern is the growing incidence of drug resistant strains of Salmonella spp. 
isolated from swine farms, slaughter houses, and retail products over the last decade (7, 57, 
58, 62, 96, 159, 161, 173). Drug resistant Salmonella spp. may increase morbidity and 
mortality in humans due to difficulty in treatment (170). This is unfortunate when the 
transmission is due to food production because this seems to be a preventable problem (69, 
161, 163, 173). Combining its ability to cause foodborne illness with the increasing 
incidence of drug resistance Salmonella infection is a major issue to address with regard to 
human health worldwide (8, 115, 132). The impact of effective alternatives for controlling 
this pathogen in food animals would be of great public health significance (23, 35, 36). 
A potential approach to control drug resistant strains of Salmonella spp. in livestock 
is the application of virulent bacteriophages (phages) capable of lysing Salmonella spp. (8, 
12, 13, 20, 120, 145). In fact, there have been many clinical trials related to the use of 
phages as pharmaceuticals, however, their therapeutic efficacy is still questionable (5, 32, 
46, 71, 134, 154). Despite the disappointing outcome obtained from early trials of phage 
therapy, the ability of virulent phages to lyse target bacteria quickly is of growing interest. 
This property of phages could potentially be a valuable intervention strategy for antibiotic 
resistant Salmonella spp. (5, 110, 134, 152). Accordingly, the present study was conducted 
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to evaluate the potential of phages for the reduction of Salmonella serovar Typhimurium in 
acutely infected pigs. The overall goal of the study was to test the usefulness of phage 
treatment as a short-term intervention strategy against Salmonella spp. in swine 
immediately prior to the slaughter. 
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CHAPTER 2. LITERATURE REVIEW 
Salmonella spp. 
Salmonella spp. are facultative anaerobic Gram-negative bacteria in the family 
Enterobacteriaceae (94, 132). Since their initial report as an "enteric fever agent" of 
animals in 1822, several microorganisms have been subsequently isolated, identified, and 
finally named Salmonella (82, 94, 129, 132). To date more than 2,400 serovars of 
Salmonella have been identified according to their antigenic schemes (129). It has recently 
been suggested that the Salmonella genus should be classified into two species: Salmonella 
enterica and Salmonella bongori (64, 129). 
Salmonella spp. are generally defined as intestinal bacteria of vertebrates but are 
found ubiquitously in nature (8, 18, 132). Some serovars of Salmonella cause disease only 
when they infect susceptible host animals (termed host-adapted serovars). These serovars 
include: Typhi, Paratyphi, Dublin, Choleraesuis, Pullorum, and Gallinarium (83, 94, 132). 
On the contrary, most other serovars of Salmonella, called host non-adapted serovars, are 
able to infect nonspecifically a variety of animals but usually do not cause severe clinical 
signs of illness (8, 83). 
Foodborne illness and Salmonella spp. 
Foodborne illnesses are defined as diseases, either infectious or toxic in nature, 
caused by either known or unknown agents that enter the human body through the ingestion 
of food (159, 160). In the United States annually there are approximately 76 million 
illnesses, 325,000 hospitalizations, and 5,000 deaths due to foodborne disease (115, 160). 
More than 200 known pathogens account for 14 million cases of illness and 60,000 
hospitalizations, while unknown agents account for the remaining 62 million cases (115). 
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Among the known pathogens, Salmonella spp. are responsible for about 1.4 million cases in 
the United States each year (115, 142). 
Salmonella infection in humans primarily stems from the ingestion of contaminated 
food products of animal origin, such as poultry, beef, pork, dairy products, and sea food 
(115, 142, 161). Among the various meat sources for Salmonella spp., pork has been 
identified as an important food vehicle in outbreaks of human salmonellosis (23, 29, 172). 
Incidence of drug resistant Salmonella spp. 
A number of drug resistant bacteria are commonly found in food products, which 
become a great concern for human public health (11, 58, 67,171, 173). Among many 
emerging drug resistant bacteria, Salmonella spp. currently pose a significant problem in 
the food industry because the pathogen may be transmitted to humans through the food 
chain (57, 72,142,161, 170, 171, 173, 179). Moreover, in England, the proportion of drug 
resistant isolates in clinical samples and meat products rose from 39% in 1990 to 98% in 
1996 (162). Among drug resistant strains of Salmonella, Salmonella serovar Typhimurium 
definitive phage type (DT)104 now constitutes the second most common serovar of 
Salmonella spp. causing gastroenteritis in England and Wales (162). The increased 
incidence of drug resistant bacteria could result in regulation of antibiotic use in 
commercial animal diets, because of the possible link between excessive antibiotic use in 
the animal industry and the subsequent emergence of drug resistance (161, 173). Due to the 
potential regulation of antibiotics, many investigators are searching for alternatives to 
conventional chemotherapeutic agents as a means to prevent and treat emerging and/or re-
emerging bacterial diseases (123, 164, 171, 181). 
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Salmonella prevalence on swine farms 
Although Salmonella spp. are commonly found in nature, the main sources of 
human salmonellosis are food animals infected with the pathogen (8, 40, 132). Poultry and 
cattle have been recognized as the main reservoirs for human salmonellosis but swine are 
also a major carrier of foodbome Salmonella spp. throughout the world. The distribution of 
Salmonella spp. on swine farms is widespread and dependent on seasonal or demographic 
factors, as well as the type of production system (8). Sub-clinical infections (characterized 
by intermittent shedding of small numbers of Salmonella spp.) result in an infection-
contamination-infection cycle among pigs continually maintained with an endemic "house-
flora" of Salmonella spp. (21). 
Some studies reported that the prevalence of Salmonella spp. is between 5% and 30 
% at the end of the fattening period (21), and between 27% and 38.2% in total herds (9, 23, 
50). Moreover, a significant number of healthy pigs were found to be carriers of 
Salmonella spp., which might be a source of infection for other pigs, contamination of the 
environment or instruments, and eventually meat products in abattoirs (21, 56, 99, 118). 
Salmonella prevalence before slaughter 
The handling and transport of pigs prior to slaughter has long been recognized to 
increase the prevalence of Salmonella spp. (36, 56, 65, 74, 75, 114, 125, 176). During the 
short period for transportation and holding in lairage before slaughter, up to 20% of 
Salmonella-free pigs may become Salmonella-positive (21, 65, 118, 125). Also, isolation 
of Salmonella spp. from pork carcasses has been shown to vary between 5% and 50% 
percentages that are considerably higher than the levels of Salmonella spp. at the farms (24, 
65). In live animals in lairage there has also been an increased incidence of different 
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serovars of Salmonella, which had not been detected on swine at the farms (75, 77). The 
rise in the incidence of Salmonella spp. in pigs from farm to slaughter could be associated 
with various factors, such as direct exposure to infected pigs and/or contaminated 
environments (including transportation vehicles, pen floors, and water) (118, 176), 
transportation stress (39, 177, 178), and feed deprivation (19, 56, 81, 117, 157). Among 
these factors, Salmonella exclusion onto the pen floor by the animal infected on the farm 
are most likely the primary reservoir and source of Salmonella spp. in non-infected animals 
(21, 24, 56, 68, 157, 158). 
The rapid increase in Salmonella incidence during transportation and lairage may be 
due to the ability of Salmonella spp. to disseminate into tissues of pigs within a few hours 
after the initial challenge(51, 74, 75, 77). In one study, when pigs were exposed to a fecal 
slurry contaminated with Salmonella serovar Typhimurium, the same Salmonella was 
isolated from pig feces that was collected within 2 hours of exposure (74). Thus, 
investigators believe that animals moving from the farm to slaughter represent the major 
source of general bacterial contamination between market hogs (75, 118, 178). Taken 
together, acute infection of Salmonella spp. in pigs immediately prior to slaughter is a 
considerable risk factor to pork quality (21), resulting in increased human foodborne 
illnesses (74, 76). 
Necessity of intervention strategies against Salmonella spp. 
Salmonella spp. have been isolated at multiple points along the swine production 
line, including on the farm, holding in lairage, processing at slaughter, and in retail 
products. Salmonella contaminated animals entering a processing plant for slaughter result 
in many opportunities for the contamination of other pig carcasses and the eventual 
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transmission to the consumer (21, 24). Thus, controlling Salmonella spp. in food animals 
before entry into the slaughter process would be a crucial point in reducing the 
contamination of pork products (23, 74, 118, 158, 173). 
In many countries, efforts are being made to reduce the Salmonella burden at all 
levels of production (98, 108, 126). For example, in Denmark, the incidence of Salmonella 
spp. in swine was reduced by monitoring the level of Salmonella spp. in integrated farms 
and some slaughter houses also regulate the slaughter of pigs based on the level of bacteria 
found through on-farm surveillance in order to avoid cross-contamination between herds 
during slaughter (4, 41, 126, 158). This is not practical in the United States where swine 
farms are not integrated under government mandates. Thus, alternative approaches to 
resolve Salmonella problem are necessary in swine farm in the United States. 
Although there are several points at which control measures can be taken to 
decrease the spread of Salmonella spp. from swine to humans, the ultimate responsibility 
for producing safe pork products lies with the industry as a whole. In the long trail from 
farm to fork, on-farm activities that can be utilized to reduce the contamination would be an 
important step in reducing the incidence of foodborne illness derived from pork products 
(98, 166, 173). Due to unlikely elimination of Salmonella spp. from food animals, new 
approaches would be beneficial at the farm level either to initially reduce the of Salmonella 
spp. or to prevent further infection during holding at lairage (74, 118, 158, 173). Also, new 
methods initiated on the farm would need to target both Salmonella transmission and the 
emerging problem of antimicrobial resistance (142, 173). 
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Bacteriophage and phage therapy 
Ernest Hankin initially reported the antibacterial activity of an unidentified 
substance in the water of the Ganges river in India, in 1896 (91, 152). Several other 
investigators subsequently observed a similar phenomenon (152, 154, 155). In 1915, 
Frederick Twort reported the phenomenon may be due to the presence of a virus (165). 
Felix d'Herelle in 1917 proposed that the phenomenon was caused by a virus capable of 
lysing parasitizing bacteria, and named this type of virus bacteriophage (commonly referred 
to as phage) meaning "eating bacteria" (45, 155). 
Phages are generally defined as bacterial viruses that invade susceptible bacteria and 
multiply within the cells, and, in the case of lytic phages, finally lyse the bacteria (1-3, 26). 
Lytic phages capable of killing pathogenic bacteria have been used as therapeutic agents 
(10, 45, 155). Eagerness to further develop phages as therapeutic agents, called phage 
therapy led to extensive studies isolating and identifying phages effective against many 
pathogenic bacteria (1, 3, 5, 26, 32, 45, 155). 
Since an initial report on phage therapy against staphylococcal infection in 1921, 
there have been numerous investigations on the therapeutic use of phages for bacterial 
diseases. Most of these studies were performed in eastern Europe (46, 93, 135). However, 
therapeutic efficacy of phage therapy was uncertain due to the unpredictable outcome 
observed in the earlier investigations. Therefore, interest in phage therapy gradually faded 
away and was eventually replaced by antibiotic use in the 1940's. 
Recent trials of phage therapy 
Interest in phage therapy was renewed in the late 1960's due to the emergence of 
drug resistant bacteria (5, 32, 153). In fact, the rekindled interest in phage therapy partially 
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came from the relatively recent reports of Smith and Huggins and their collaborators (147-
149). They reported that phage treatment significantly reduced disease caused by E. coli 
infections in animals (147, 148). These studies also suggested that phage therapy may be 
superior to antibiotic treatment, and therefore the value of phage therapy should be 
reevaluated. 
Recently, Barrow et al (1998) reported that phage therapy could reduce diarrhea 
caused by E. coli in chickens for short periods following treatment (12). The remaining 
bacteria appeared to be mutants resistant to the applied phages, indicating that bacterial 
resistance to lysis by phage develops rapidly after treatment (12). Berchieri et al (1991) 
reported that the administration of a high concentration of phages (> 1010 plaque forming 
unit [PFU]/ml) significantly reduced the mortality of chickens infected with Salmonella 
serovar Typhimurium, but administration of a low concentration of phages was ineffective 
(20). They found that phage treatment reduced the levels of Salmonella by greater than 2 
logs in the intestinal tract contents at 12 hours post exposure, but were not able to eliminate 
the organism. Further more phage efficacy disappeared by 24 hours post exposure (20). 
They also reported that the Salmonella serovar Typhimurium persisted longer that the 
phage in chickens and that less than 106 colony forming unit [CFU]/ml of the 
microorganism may be insufficient to sustain phage multiplication in vivo. 
Since Smith and Williams's reports, studies on the effectiveness of phage therapy to 
cure or prevent different bacterial infections, due to Acinetobacter baumanii (150), 
Klebsiella (146), Vibrio vulnificus (33), Aeromonas hydrophila (180), Pseudomonas 
aeruginosa (131, 146, 151), Escherichia col (12, 138, 146), Salmonella serovar Enteritidis, 
Salmonella serovar Typhimurium (14, 20, 120, 145), and Enterococcusfaecium (27), have 
been performed in fish, animals, and humans. According to the results observed in these 
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studies, phage treatment reduced the numbers of target bacteria for short periods of time 
following phage treatment, but didn't eliminate the bacteria, particularly in the intestinal 
tract. Recently, phage administration has been evaluated as a possible intervention strategy 
for foodborne pathogens in pigs (120) and chickens (13, 20, 73, 145). 
Lytic phages also have enzymes capable of degrading the peptidoglycan layers of 
target bacteria, eventually causing lysis of target bacteria. These enzymes are thought to be 
possible candidates for development as phage-based therapeutic agents against antibiotic 
resistant bacteria. Phage-based enzymes have been successfully used to treat mice infected 
with Streptococcus pneumoniae (109, 124) and Bacillus anthracis (143). 
Salmonella phages 
When phage infects a susceptible host cell, one of the most critical factors is the 
ability of the phage adsorbed onto particular components of outer membrane of bacteria 
(17, 88, 102). The adsorption process of the phage to the host cell occurs through 
enzymatic interaction between tips of the tail fibers of the phage and the receptor sites of 
the host cell (102, 103, 106, 107). Due to affinity between the phage tips and receptor sites, 
a single phage usually adsorbs to a specific host cell that has a primary receptor site 
available for the phage, but not host cells that lack the receptor site (102, 106). 
The structure of Salmonella includes a lipopolysaccharide (LPS) coat on the outer 
membrane. This membrane consists of an inner core of covalently linked lipids and 
carbohydrates from which the O-antigen side chains (consisting of oligosaccharide 
repeating units) branch out (112, 121, 128, 130, 141). The core region of LPS is nearly 
constant between serovars of Salmonella, whereas O-side chains are composed of various 
combinations of monosaccharides and aligned in different ways. Thus, the O-antigen side 
12 
chains are highly variable, and structurally dependent on the serovars and phase variation of 
Salmonella (102, 106, 107, 128). Accordingly, the O-antigen side chains represent the 
determinant structure for Salmonella antigens and serve as the receptor sites for phages 
(111, 137). Thus, the susceptibility of Salmonella to phage infection is based on the 
presence of these receptor sites on the LPS (112, 128). 
Salmonella outer membrane structure 
Phenotypes of Salmonella are classified according to the outer membrane structure, 
and consist of smooth-, rough-, and semi rough-type strains. Smooth strains have an intact 
LPS structure including complete O-antigen side chains and core region, whereas rough 
strains have on incomplete LPS structure with a complete core but no O-antigen side 
chains. Semi rough strains also have incomplete LPS with a complete core and only one or 
a few O-antigen chains (107, 128). Phages are classified on the basis of their lytic activity 
to the different types of Salmonella, and are determined to be smooth-, rough-, or semi 
rough-specific phages (106, 137). The schematic structure of LPS of Salmonella is shown 
in Figure 1. 
Smooth-specific phages 
Most Salmonella phages can infect only smooth strains of Salmonella that have 
complete O-antigen repeating units and an intact core region of LPS. They attach to the 
receptor sites on the O-antigen repeating units (139). These phages include P22, P22 
derivates, ES18, £, E15, g341, A3, 9NA (137,175). Of the smooth-specific Salmonella 
phages, P22, a well characterized phage, is capable of infecting most smooth strains of 
Salmonella carrying O-antigen factor 12, which is shared in Salmonella serogroups A, B, 
and D 1• However, P22 cannot infect smooth strains of Salmonella that do not have the 
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appropriate antigenic factor 12 (48, 137, 182). Accordingly, smooth specific phages are 
usually able to lyse a narrow range of host bacteria since the chemical and physical 
structure of O-antigen repeating units is highly variable and serovar-specific (95, 102, 103, 
106, 107). 
Rough-specific phages 
Rough-specific phages can adsorb to most classes of rough mutants of Salmonella 
(137). These phages include Ffm, Br2, Br 10, Br60, FPl, FP3, 6SR, cp, Xl 74, S13 (137, 
175). These phages can lyse a broad-range of rough strains of Salmonella because their 
receptor sites are located on the LPS core region that is fairly well conserved between 
serovars. They can not lyse smooth strains of Salmonella, possibly, because long O-antigen 
side chains hinder the access of the phages to the receptor sites on the core region of LPS 
beneath the O-antigen repeating units (30, 107). Overall, rough-specific phages are not 
good candidates for phage therapy against Salmonella infection because most pathogenic 
Salmonella are smooth strains. 
Semi rough-specific phage 
F0-1 phage has been recognized as a unique semi rough-specific Salmonella phage 
that was initially isolated by Felix d'Herelle in 1945 (52). The F0-1 phage is capable of 
lysing semi rough, Ra chemotype rough, and most smooth strains of Salmonella belonging 
to a variety of serogroups. Cherry et al (1954), and Kallings et al (1967) reported that 90-
99% of all Salmonella spp. tested were sensitive to this phage under favorable conditions 
(13, 34, 85, 87, 112). Thus, phages are able to lyse a broad range of Salmonella serovars 
due to the phage's capacity to adsorb to N-acetylglucosamine, which branches from the 
core region of LPS, and present in almost all Salmonella spp. (85, 107). Strains of 
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Salmonella lacking of N-acetylglucosamine in LPS are resistant to this phage (105). The 
ability of F0-1 phage to lyse most smooth strains of Salmonella makes it beneficial for 
therapeutic use against Salmonella infections (95, 107). 
Negative aspects of phage therapy 
The properties of lytic phages would seem to make them good candidates for 
clinical trials because the phages act as lethal agents to kill target bacteria in vitro. There 
have been numerous clinical trials using phage therapy in animals and humans (1, 3, 32, 
152). However, the results observed in the early trials were unpredictable, resulting in 
controversy with regard to the efficacy of phage therapy (152, 154). Many factors 
contribute to the unpredictable effect of phage therapy. As with antibiotics, resistance of 
the bacteria to phages develops (20), which can hamper the effectiveness of the treatment 
(152). Also, the narrow specificity of smooth-specific phages to host bacteria may be an 
important issue (5, 15). The problem associated with the narrow specificity of the phages 
likely increases when a single smooth-specific phage is used to control smooth strains of 
bacteria that lack the receptor sites necessary for the applied phage. To resolve this 
problem, the use of either a phage cocktail consisting of phages with different specificities 
or a single broad-host range phage has been suggested (15, 95, 145). In applying phages 
for a therapeutic purpose, their short retention time in vivo is another challenge because 
they are quickly cleared from the circulation in phage-treated animals (116)(20, 59, 79, 80, 
138). 
The concentration of phage particles administered may also influence the outcome 
of therapy (12, 20, 150, 152). In order to anticipate the outcome, Payne et al (2000) 
suggested a mathematical model based on the population dynamics between phages and 
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target bacteria in vivo. This model suggested that most phage particles in vivo may attack 
the target bacteria through their extensive replication, called "active effect", or may be 
diminished in the presence of bacteria that are below the minimum concentration required 
for phage replication, called the "critical threshold" (134, 174). However, when the initial 
phage particles inundate the bacteria in vivo, they can also kill the bacteria non-specifically, 
called the "passive effect" (49, 134). Thus, phage therapy may work only when the density 
of target bacteria exceeds a critical threshold in vivo, or when huge amounts of phage 
particle are used (13). This model may provide a clue for understanding the unpredictable 
results observed in the earlier studies on phage therapy. 
Another problem with phage therapy can be attributed to the fact that some bacteria, 
such as Salmonella, Brucella, Mycobacterium, are located intracellularly at a certain stages 
of their infection cycle where phage particles can not access them (13, 15, 20, 38). Without 
the aid of the cell-mediated immune system of phage-treated animals, phage therapy alone 
may not work effectively against these kinds of bacteria (12, 15, 100, 152). Also of 
importance are the phage-encoded genes carried by some phages for toxins or virulence 
factors, which can be transferred horizontally between bacteria (44, 78, 119, 169). 
Therefore, the transfer of virulence genes into other target bacteria due to phage therapy 
could be possible (32, 152). Thus, the genetic or physiological properties of phages, the 
interaction between phages and host, and the bacterial pathogenesis of target bacteria are all 
aspects of phage therapy that must be considered (3, 89, 95, 97, 100, 101, 139). 
Phages as a potential antibiotic alternative 
Earlier investigators believed that phage treatment would be effective to cure 
bacterial diseases. Current results observed in studies of phage therapy indicate that the 
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therapeutic value of phage therapy seems unlikely. Nevertheless, there is a great interest in 
the properties of phage particles capable of killing drug resistant bacteria (5, 12, 116, 145). 
There are two possible approaches to utilize phages as alternatives for dealing with 
drug resistant bacteria. First, extremely high concentration of intact phage particles may be 
utilized to reduce the levels of Salmonella spp. in livestock for a certain period of time (13, 
15, 20), which would be a short-term intervention strategy. This theory is based on the 
ability of phage to lyse target bacteria at a high multiplicity of infection, called "lysis from 
without", or "immediate lysis" (49) . The efficacy of phage application as a short-term 
intervention strategy against Salmonella in pig was evaluated in the study reported here. 
A second approach would be to utilize phage-associated enzymes purified and 
applied for the purpose of eliminating Salmonella spp. from animals. Unlike antibiotics, 
the phage-associated enzymes degrade physically the cross-linkage of peptidoglycan layer 
located in the membrane of bacteria (49). This would be beneficial because bacteria 
unlikely develop resistance to this lytic mechanism. This would be a true alternative to 
conventional antibiotics for dealing with drug resistant bacteria. 
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CHAPTER 3. MATERIALS AND METHODS 
Experiment 1: Isolation of phages capable of lysing several serovars of 
Salmonella from swine and human sewage samples 
Bacteria 
Salmonella serovar Typhimurium=strain x4232 NalR was used for isolating phages 
capable of lysing Salmonella spp. from sewage samples. This strain was obtained from Dr. 
Scott Hurd at the United States Department of Agriculture (USDA) in Ames, IA. Several 
other serovars of Salmonella were used to screen the lytic activity of the isolated phages 
against Salmonella spp .. These serovars were obtained from the National Veterinary 
Service Laboratory (NVSL) in Ames, IA and a previous study conducted at Iowa State 
University (47). The following Salmonella serovars were included: Typhimurium, 
Typhimurium variant Copenhagen, Agona, Heidelberg, Enteritidis, Anatum, Brandenburg, 
Choleraesuis, Choleraesuis variant Kunzendorf, Derby, Mbandaka, Thompson, Infantis, 
Oranienburg, Newport, Munchen, and Javiana. Each of these is found frequently in swine 
in North America (9, 42, 43, 47, 53, 55, 136). 
Phage isolation 
Sewage samples were obtained from swine farms and a human waste treatment 
facility in order to isolate phages capable of lysing Salmonella spp. Phages were isolated 
by a enrichment method as described previously (63). Briefly, 45 ml of each sample was 
mixed with 5 ml of l0x brain heart infusion (BHI) broth, CaC}z solution (at a final 
concentration of 1 mM), and Salmonella culture (at a final concentration of 107 colony 
forming unit [CFU]/ml). After the mixture was incubated at 37°C overnight, the 
supernatant of the mixture was obtained by a centrifugation at 1,300 g for 90 minutes at 
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4°C and then filtered with a membrane filter (0.45 µl in a diameter). One milliliter of the 
filtered supernatant was transferred into 5 ml of Luria-Bertani (LB) broth containing CaCii 
(at a final concentration of 1 mM), and Salmonella culture (at a final concentration of 107 
CFU/ml). The mixture was incubated for 15 minutes at 37°C, and thoroughly mixed with 
an equal volume of 2x phage agar concentrate (PAC) (14 g meat extract, 4 g yeast extract, 
12 g peptone, 4 g NaCl, 1 g Na2CO3, 1 g MgC12, and 12 g Bacto agar in 1,000 ml of pure 
water, adjusted to pH 7.2), which was pre-melted and kept at 42°C. The entire mixture was 
then poured as a 0.5 mm thin-layer of agar into a Petri dish, and incubated at 37°C 
overnight. A single clear plaque was picked from the plate and further purified through a 
serial plaque assay. Finally, individual stocks of the isolated phages were stored at 4°C. 
Host range of isolated phages 
The host range of isolated phages to various serovars of Salmonella was determined 
by a previous method (60, 113). Briefly, 1 ml of Salmonella culture (with a final 
concentration of 108 CFU/ml) was coated on a Trypticase Soy Agar (TSA) plate, with 
immediate removal of excess fluid from the agar surface. Once the plate dried, 20 µl of 
each phage lysate (with a final concentration of 108 plaque forming unit [PFU]/ml) was 
dropped on the Salmonella coated agar surface. After the drop of phage stock was 
completely absorbed, the plate was incubated overnight at 37°C. The results were either 
confluent lysis or formation of phage plaques on the lawn growth of Salmonella ( + ), or 
unbroken growth of Salmonella or no formation of phage plaques (-), as shown in Figure 1. 
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Experiment 2: An attempt to reduce the levels of Salmonella serovar 
Typhimurium in pigs with application of a phage cocktail 
Salmonella 
Salmonella serovar Typhimurium X4232 NalR, which had been used for isolating 
phages, was also used for challenging pigs. The microorganism is resistant to nalidixic 
acid, which was used as a selection marker. For preparing Salmonella inoculum, a streak of 
frozen stock of Salmonella serovar Typhimurium X4232 NalR was inoculated into 10 ml of 
LB broth and incubated at 37°C overnight. Then 250 µl of the broth culture was transferred 
into 25 ml of LB broth in a 250 ml baffled-flask and incubated in a shaking incubator at 200 
rpm and 37°C for approximately 5 hours. Salmonella was harvested by a centrifugation at 
3,000g for 20 minutes at 4°C. The Salmonella pellet was re-suspended with phosphate 
buffered saline (PBS). The concentration of Salmonella was adjusted to lxl08 CFU/ml in 
PBS. One ml of the Salmonella preparation was instilled into each nostril of pigs and 
swallowed. Pigs in the negative control group received one ml of LB broth in each nostril 
in the same manner. 
Preparation of a phage cocktail 
Each phage lysate of the isolated phages was produced by a semi-solid culture 
method. Briefly, a small volume of each phage stock (lx108 PFU/ml) obtained from 
Experiment 1 was added into 5 ml of LB broth containing CaCh (a final concentration of 1 
mM), and Salmonella (at a final concentration of 108 CFU/ml). After incubation of the 
mixture for 15 minutes at 37°C, the mixture was mixed with an equal volume of 2x PAC, 
which was pre-melted and warmed at 42°C. It was poured into a Petri-dish plate and 
incubated at 37°C overnight. The agar cultured overnight was minced and centrifuged to 
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harvest the supernatant of the culture. One hundred mjcroliters of 26 individual phage 
stocks were mixed in the total volume of volume of 2.6 ml, which had the total 
concentration of phage particles of 2.6 x 109 PFU. 
Animal preparation 
Three-week-old pigs were purchased from a farm in Iowa and housed in a confined 
animal facility at Iowa State University. Throughout experiment, the pigs were fed with 
irradiated conventional diets and water ad libitum. During an acclimatization period of one 
week in the isolation facility, the Salmonella-free status of the pigs was confirmed by 
bacteriological and serological methods as described below. Only animals confirmed to be 
Salmonella-negative bacteriologically and serologically were used. 
Screening the status of Salmonella in animals 
For a bacterial culture, pen fecal and individual rectal swabs of the pigs were 
collected at their arrival date and one week post arrival. Buffered Peptone Water (BPW) 
was added to the samples at a dilution of 9 ml to 1 g of fecal sample, or 9 ml to 1 rectal 
swab. After incubation at 37°C overnight, 100 µl of the BPW culture were transferred into 
9 ml of Rapparport-Vassiliads (RV) medium and incubated at 42°C overnight. The next 
day, 100 µl of the RV culture were transferred and spread onto XLD agar plate and 
incubated 37°C overnight. Five suspected Salmonella colonies on XLD plates were picked 
and further tested by biochemical tests, including Klinger's iron agar (KIA), sulfur-indole-
motility (SIM) agar, phenylalanine agar, lysine iron agar, urease agar, and slide 
agglutination tests with Salmonella O-antisera. For a serological assay, blood was collected 
from individual pigs at their arrival date and one week post arrival, as well. Sera were 
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collected and tested using the Danish-mix-ELISA test (127). An optical density percent 
(O.D. % ) of 20 or less was considered to be a negative reading in the assay. 
Animal trial with phage cocktail treatment 
The pigs were assigned into 4 groups (5 pigs/group): one Salmonella challenge 
group (positive control group), and three phage-treated groups (treatment group). The 
phage cocktail in these treatment groups was administered via intramuscular (IM), 
intraperitoneal (IP), or oral (Oral) routes, respectively. The pigs in the positive control 
group were challenged with Salmonella serovar Typhimurium but not treated with the 
phage cocktail. Administration of the phage cocktail (at the total volume of 2.6 ml) 
occurred in all three groups 18 hours after the Salmonella challenge, while the positive 
control group received an equal volume of filtered Salmonella-culture Iysate (without phage 
particles). Twenty-four hours after administration of the either a phage cocktail or 
Salmonella-culture lysate, two pigs in every group were sacrificed to evaluate the levels of 
Salmonella in their tissues. The remaining 3 pigs in all groups were sacrificed at 48 hours 
after administration of the phage cocktail. At necropsy, tissue samples were collected as 
follows: tonsil, mesenteric lymph node (MLN), ilea! content, cecal content, blood, liver, 
lung, and spleen. 
Quantification of Salmonella in tissues 
The levels of Salmonella in the collected samples were determined quantitatively by 
a direct spread method. Briefly, each sample of approximately 3-5g was weighed and 
homogenized with a tissue grinder, then diluted by 10-fold dilution in PBS. One hundred 
microliters of each dilution were immediately transferred and spread onto XLD agar plate 
containing 50 µg/ml of nalidixic acid and incubated at 37°C overnight. 
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Salmonella shedding was determined by collected fecal samples at four different 
time points: D+0 hour (immediately prior to Salmonella challenge), D+ 18 hours 
(immediately prior to phage cocktail treatment), D+42 hours (24 hours after phage cocktail 
treatment), and D+66 hours (48 hours after phage cocktail treatment). The collected fecal 
samples were processed as described above. 
Statistical analysis 
The numbers of Salmonella recovered from the samples were calculated as a CFU/g 
of the samples, and converted into logarithmic values. Then, average numbers and the 
standard error for each group were determined. Any statistical difference of Salmonella 
levels between a Salmonella-positive control group and each phage-treatment group with 
the phage cocktail treatment was analyzed by the Student's t-test with SAS software. A p-
value less than 0.05 indicated a statistically significant difference between two groups. 
Experiment 3: Lytic activity of F0-1 phage against several serovars of 
Salmonella 
Bacteria 
Salmonella serovar Typhimurium X4232 NalR was used to propagate F0-1 phage. 
Other serovars of Salmonella were acquired from NVSL and a previous study. They were 
Salmonella serovars Typhimurium, Typhimurium variant Copenhagen, Agona, 
Brandenburg, Derby, Choleraesuis variant Kunzendorf, Choleraesuis, Heidelberg, 
Enteritidis, and Anatum. Also, seven strains of multi-drug resistant (MDR) Salmonella 
serovar Typhimurium DT104 were obtained from NVSL, Centers for Disease Control and 
Prevention (CDC) in Atlanta, GA, and the Minnesota Department of Health (MDH). All 
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Salmonella serovars were used to evaluate the lytic activity of F0-1 phage through an in 
vitro assay. 
F0-1 phage preparation 
The F0-1 phage was obtained from the Salmonella Genetic Stock Center (University 
of Calgary, Canada). The F0-1 phage stock was produced by a semi-solid agar method as 
described in Experiment 2. The concentration of phage particles in the supernatant was 
adjusted to 1 x 108 PFU/ml. 
Host range of F0-1 phage 
The lytic activity of F0-1 phage against several serovars of Salmonella was 
determined by a spot test as described previously (60, 113). The procedure for the spot test 
followed the same method as described in the section of host range of isolated phages in 
Experiment 1. 
Experiment 4: Establishment of an acute infection model of Salmonella 
serovar Typhimurium in pigs 
Salmonella 
Salmonella serovar Typhimurium X4232 NalR inoculum was prepared as described 
in Experiment 2. The concentrations of Salmonella were adjusted to lx 108 and 1 x 105 
CPU/ml in PBS, respectively. 
Animals preparation 
Three-week old pigs were purchased from a swine farm in Iowa and housed in a 
confined animal isolation facility at Iowa State University. Throughout the entire period of 
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this experiment, the pigs were handled by the same procedure as described in Experiment 2. 
The Salmonella-free status of the pigs was confirmed by the same method described in 
Experiment 2. Only animals that were bacteriologically and serologically confirmed to be 
Salmonella-negative were used for this study. 
Acute infection model of Salmonella serovar Typhimurium in pigs 
To demonstrate an acute infection model, pigs were randomized into three groups; 
group 1 (3 pigs) challenged with lxl08 CFU of Salmonella, group 2 (3 pigs) challenged 
with lxl05 CFU of Salmonella, and group 3 (2 pigs) as a negative control. The Salmonella 
challenge was done by the same method as describe in Experiment 2. Three hours after 
Salmonella challenge, all pigs were euthanized and necropsied. At necropsy, the following 
samples were collected: blood, liver, tonsil, lung, spleen, ileoceal lymph node (ICLN), cecal 
content, and rectal content. 
Qualitative analysis of Salmonella in tissues 
For a qualitative analysis of Salmonella, 3-5 g of tissues were macerated by a 
hammer in sample bags, and BPW broth added at the rate of 9 ml to lg of samples. After 
incubation at 37°C overnight, 100 µl of the BPW culture were transferred into 9 ml RV 
broth and incubated at 42°C overnight. The next day, 100 µl of the RV culture were 
transferred and spread onto XLD agar plate containing 50 µg/ml of nalidixic acid as an 
antibiotic selective marker, and incubated at 37°C overnight. Suspected Salmonella 
colonies on XLD plates were further confirmed by a slide agglutination test with 
Salmonella O-antiserum group B. 
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Statistical analysis 
The statistical significance of the qualitative data of Salmonella-positive samples 
present between the two challenge groups was analyzed by a Fisher Exact test. This 
analysis compared the same tissues between the two groups and pooled tissues of each 
group between two challenge groups. 
Experiment 5: Reduction of Salmonella serovar Typhimurium in pig by 
the administration of a single dose of F0-1 phage lysate 
Salmonella 
Salmonella serovar Typhimurium strain X4232 NalR was used for propagating F0-1 
phage and challenging pigs. Salmonella inoculum was prepared by the same method as 
described in Experiment 2. The concentration of Salmonella was adjusted to 5x108 CFU/ml 
in PBS. 
Phage preparation 
A small amount of F0-1 phage stock was inoculated into 100 ml of pre-warmed 
(37°C) glycerol-casamino acids [GCA] medium (88) (52.5 g Na2HPO4, 22.5 g KH2PO4, 
1.25 g ~Cl, 0.75 g MgSO4.7H2O, 18.75 g casamino acids, 37.5 ml glycerol, and 1.25 g 
gelatin in 1,000 ml of pure water), containing Salmonella (at a final concentration of 108 
CFU/ml) at the ratio of 1 to 5 multiplicity of infection (MOI). After incubation for 15 
minutes at 37°C without agitation, the culture was incubated in a shaking incubator at 150 
rpm and at 37°C for 6 to 8 hours. The culture was centrifuged at 8,000 g at 4°C for 30 
minutes and the supernatant was filtered through a membrane filter (0.45 µm in a diameter). 
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The concentration of phage particles in the supernatant was 1 ~2 x 1010 PFU/ml. The phage 
lysate was stored at 4°C until used for animal trials. 
Animal preparation 
Three-week old pigs were purchased from a swine farm in Iowa and housed in a 
confined animal isolation facility at Iowa State University. Throughout the entire 
experiment, the pigs were screened to confirm their Salmonella-free status by the same 
method as described in Experiment 2. Only animals that were bacteriologically and 
serologically confirmed to be Salmonella-negative were used. 
Animal trial with F0-1 phage 
The pigs were assigned into three groups: phage treatment group (5 pigs), 
Salmonella challenge positive control (5 pigs), and a negative control group (1 pig). All 
pigs, with the exception of the pig in the negative control group, were challenged with 
Salmonella by the same method as described in Experiment 2. Three hours after 
Salmonella challenge, pigs received either a F0-1 phage preparation (for phage treatment 
group) or the filtrate of sonicated Salmonella-culture (for the positive control group) as a 
sham via both oral (20 ml) and intramuscular [IM] (6ml) routes. Nothing was administered 
to the pig that was the negative control. Six hours after the phage treatment (at 9 hours 
after initial Salmonella challenge), the pigs were euthanized and necropsied to collect tissue 
samples. At necropsy, the samples collected were tonsil, spleen, liver, lung, ileocecal 
lymph node, cecal content, and rectal content. 
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Quantification of Salmonella in tissues 
The quantification analysis of Salmonella in the tissues was done by the same 
method as described in Experiment 2. 
Phage-susceptibility of Salmonella recovered from phage-treated pigs 
Salmonella serovar Typhimurium was recovered from some tissues, such as 
ileocecal lymph node, cecal and colon contents, in the pigs that had treated with F0-1 phage 
lysate by the same procedure as described in the quantitative assay. Colonies grown on 
XLD plates were picked and sub-cultured on TSA plates 3 times. The susceptibility of the 
recovered Salmonella to the F0-1 phage was conducted by the same procedure as described 
in determining host range of the F0-1 phage (175). 
Statistical analysis 
Statistical analysis of the data obtained from this study was done by the same 
method as described in Experiment 2. 
Experiment 6: Reduction of Salmonella serovar Typhimurium in pigs by 
the administration of multiple doses of F0-1 phage lysate 
Salmonella 
Salmonella serovar Typhimurium X4232 NalR was used to propagate F0-1 phage 
and challenge pigs. Salmonella inoculum was prepared by the same method as described in 
Experiment 2. The concentration of Salmonella for all animal trials in this section was 
adjusted to 5 x 109 CFU/ml in PBS. 
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Phage preparation 
For animal trials, a large amount of F0-1 phage 1 ysate was prepared by the same 
procedure as described in Experiment 5. 
Animal preparation and experimental groups 
Three-week old pigs were purchased from swine farms in Iowa and housed in 
confined animal isolation facilities at Iowa State University. Throughout these animal 
trials, the pigs were handled and screened to confirm their Salmonella-free status by the 
same method as describe in Experiment 2. Only animals that were bacteriologically and 
serologically confirmed to be Salmonella-negative were used. 
For each animal trial in the present study, the pigs were assigned into 3 groups: 
Salmonella positive control group (5 pigs), phage treatment group (5 pigs), and a negative 
control group (1 pig). 
Animal trial 1 
One hour after Salmonella challenge, the pigs in the phage-treated group were 
administered a F0-1 phage preparation via both IM (6 ml) and oral (20 ml) routes. They 
were also subsequently administered 15 ml of the phage preparation via oral route at 3, 5, 
and 7 hours after Salmonella challenge. The pigs in the positive control group were 
challenged and received an equivalent volume of the filtered Salmonella-culture (sham) in a 
same manner and time. No challenge was administrated to the negative control group. Pigs 
were sacrificed at 12 hours after an initial Salmonella challenge and samples [tonsil, 
ileocecal lymph node, colon and cecal content, rectal content, blood, lung, liver and spleen] 
were collected. 
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Animal trial 2 
One hour after Salmonella challenge, the pigs were administered either the phage 
preparation (for phage treatment group) or the sham (for positive control group) as 
described above. The phage preparation (15 ml) was subsequently given to the pigs in the 
phage treatment group at 2 and 3 hours after Salmonella challenge, whereas the pigs in 
positive control group received the sham (15 ml) at 2 and 3 hours after challenge. No 
challenge was administered to the negative control group. Five hours after Salmonella 
challenge, tissues [tonsil, ileocecal lymph node, colon and cecal content, rectum, blood, 
lung, liver and spleen] were collected from the sacrificed pigs. 
Animal trial 3 
One hour after Salmonella challenge, the pigs in the phage-treated group and 
positive control groups received either the phage preparation or the sham as described in 
animal trial 1 and received another administration (15ml) via oral route at 2 hours after the 
initial Salmonella challenge. Neither challenge was administered to the negative control 
group. Three hours after Salmonella challenge, all pigs were sacrificed and samples [tonsil, 
ileocecal lymph node, colon and cecal content, rectum, blood, lung, liver and spleen] were 
collected. 
Quantification of Salmonella in tissues 
At necropsy, the following samples were collected: tonsil, ileocecal lymph node, 
colon content, cecal content, rectal content, blood, lung, liver, and spleen. The quantitative 
analysis of the levels of Salmonella in the tissues was as described in Experiment 2. 
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Statistical analysis 
Statistical analysis also followed the same method as described in Experiment 2. 
Experiment 7: Comparison of the effectiveness of F0-1 phage in reducing 
Salmonella serovar Typhimurium levels in pigs by different 
administration routes 
Salmonella 
Salmonella serovar Typhimurium x4232 NalR was used to propagate F0-1 phage 
and challenge pigs. Salmonella inoculum was prepared as described in Experiment 2. The 
concentration of Salmonella was adjusted to 5 x 109 CFU/ml in PBS. 
Phage preparation 
A large amount of F0- lphage lysate was prepared as described in Experiment 6. 
The concentration of phage particles in the supernatant was 1 ~2 x 1010 PFU/ml. The phage 
preparation was stored at 4 °C until used for animal trials. 
Animal preparation 
After purchasing three-week old pigs from swine farms, all procedures for animal 
preparation were the same to those as described in Experiment 2. Only animals that were 
bacteriologically and serologically confirmed to be Salmonella-negative were used. 
Animal trial 
The pigs were assigned into four groups: one Salmonella challenge positive control 
group (5 pigs), phage treatment group via IM+oral route (5 pigs), phage treatment group via 
oral route (5 pigs), and a negative control group (2 pigs). As described in Experiment 6 
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(Animal Trial 1), one hour after Salmonella challenge, the pigs in Salmonella positive 
control group received the sham (20 ml) via oral route, whereas the pigs in one phage 
treatment group received the phage preparation via oral (20ml) and IM 9 (6ml) routes, and 
the pigs in the other phage treatment group received the phage preparation via only the oral 
(20ml) route. The pigs in the Salmonella positive control group received subsequent 
treatments of 15 ml of the sham via only oral route at 3, 5, 7 hours after Salmonella 
challenge. The pigs in both phage-treatment groups received subsequent treatment of 15 ml 
of phage preparation via oral route at the same times. Neither Salmonella challenge nor 
phage-treatment was administered to the two pigs in the negative control group. Twelve 
hours after initial Salmonella challenge, all pigs were euthanized and necropsied to collect 
tissue samples. The samples were tonsil, cecal content, colon content, mandibular lymph 
node, liver, ileoceal lymph node, and spleen. This animal trial was replicated. 
Quantification and qualification of Salmonella in tissues 
The quantitative analysis of Salmonella in tonsils, cecal and colon contents was 
done as described in Experiment 2. The levels of Salmonella in mandibular lymph node, 
liver, ileocecal lymph node, and spleen were determined qualitatively as described in 
Experiment 3. 
Statistical analysis 
Quantitative data were analyzed by Student's t-test as described in Experiment 2, 
whereas qualitative data were analyzed with a Fisher Exact test as described in Experiment 
4. 
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CHAPTER4.RESULTS 
Experiment 1: Isolation of phage capable of lysing several serovars of 
Salmonella from swine and human sewage samples 
Isolation of phages 
Phages capable of lysing several serovars of Salmonella were isolated from a variety 
of samples which included fecal and lagoon materials from animal farms (including cattle, 
sheep, and swine), and a fermented liquid sample from a human waste treatment facility 
(Table 1). In this study we isolated 26 different phages (Table 2). Since further studies 
have not been done to differentiate the isolated phages, the possibility that either similar or 
the same phages exist among 26 phages could not be excluded in the present study. The 
plaque sizes of the phages ranged from 0.2 mm to 2 mm on phage agar plates (with 0.6 % 
agar)(Figure 2). 
Host range of isolated phages 
All phages lysed Salmonella serovar Typhimurium (Table 2). They also lysed 
serogroup Band D 1, which shares an antigenic factor. In contrast, Salmonella serogroup 
C2, E 1 and 0 2 appeared resistant to most isolated phages, except two phages, isolates HL03 
and HL18. These two phages lysed more Salmonella serovars than any of the other phages 
(Table 2). All phages left colonies growing within the lytic spot area (Figure 1), called 
secondary colonies, indicating that the lysis was incomplete. 
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Experiment 2: An attempt to reduce the levels of Salmonella serovar 
Typhimurium in pigs with application of a phage cocktail 
Shedding numbers of Salmonella in fecal samples 
No statistically significant differences were found in the numbers of Salmonella 
shed in the feces among phage cocktail administration via different routes, regardless of 
different end time points (24 or 48 hours post phage cocktail treatment)(Table 3). 
Salmonella levels in tissues at 24 hours after phage cocktail treatment 
In pigs sacrificed at 24 hours after IP administration of the phage cocktail, the levels 
of Salmonella were slightly reduced only in mesenteric lymph nodes but not other tissues 
(Table 4 ). Also, administration of the phage cocktail via the oral route reduced slightly the 
levels of Salmonella in ileum contents but not cecal contents. The levels of Salmonella in 
cecal contents were slightly lower in the pigs given the phage cocktail via IM route. The 
degree of all reductions observed in this time point was not statistically significant. 
Salmonella levels in tissues at 48 hours after phage treatment 
Regardless of different administration routes of the phage cocktail, the levels of 
Salmonella in all tissues of phage-treated pigs were not statistically different from those of 
the pigs in phage-untreated group (Table 5). On the contrary, the levels of Salmonella in 
some tissues were higher than in the phage-treated group. 
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Experiment 3: Lytic activity of F0-1 phage against serovars of Salmonella 
Host range of F0-1 phage against Salmonella 
In an in vitro assay, the F0-1 phage effectively lysed all serovars of Salmonella 
tested, which included serogroup B, C 1, and D 1 that represent the 10 major serovars most 
frequently found in swine farms (Table 6). 
Lytic activity against multi-drug resistant Salmonella 
As shown in table 7, F0-1 phage lysed effectively all strains of multi-drug resistant 
Salmonella tested which were derived from all different locations (Table 7). 
Experiment 4: Establishment of an acute infection model of Salmonella 
serovar Typhimurium in pigs 
Salmonella serovar Typhimurium rapidly disseminated into most tissues (except 
blood and lungs) at 3 hours after an initial challenge via intranasal route. Twelve out of 24 
pooled tissues (50%) obtained from the pigs challenged with 108 CFU of Salmonella were 
positive for Salmonella (Table 8). In contrast, 6 out of 24 pooled tissues (25%) were 
positive for Salmonella in pigs challenged with 105 CFU (Table 8). The rate of Salmonella-
positive tissues varied between high (6 out of 8) and low (3 out of 8) challenge doses. 
However, no statistically significant difference in the rate of Salmonella-positive tissues 
was found between the two challenge groups (105 or 108 CFU) by a Fisher Exact test (P = 
0.07). Additionally, no statistically significant difference was found between individual 
tissues, or pooled tissues of the two groups. 
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Experiment 5: Reduction of Salmonella serovar Typhimurium in pigs by 
the administration of a single dose of FO-lphage lysate 
Administration of a single dose of F0-1 phage lysate significantly reduced the levels 
of Salmonella in tonsil and cecal contents in the pigs in the phage-treated group, compared 
to those of phage-untreated control group (P < 0.01) (Table 9). Also, the levels of 
Salmonella in ileoceal lymph node were slightly reduced by the phage administration. In 
other tissues, Salmonella levels were not determined quantitatively due to the limits of the 
utilized method as described previously. Meanwhile, Salmonella levels in the cecal content 
remained at 5 logs after phage treatment (Table 9). 
Susceptibility of the recovered Salmonella from pigs to F0-1 phage 
One hundred eighty-seven colonies of Salmonella serovar Typhimurium were 
recovered from the tissues in the pigs that received a single dose of F0-1 phage lysate after 
Salmonella challenge. They originated from ileocecal lymph node (ICLN) (12 colonies), 
cecal contents (161 colonies), and colon content (14 colonies). All of these isolates were 
susceptible to F0-1 phage. 
Experiment 6: Reduction of Salmonella serovar Typhimurium in pigs by 
the administration of multiple doses of F0-1 phage lysate 
Animal trial 1 
Multiple administrations of phage lysate significantly reduced the levels of 
Salmonella in tonsil, colon, and cecal content (P < 0.01) (Table 10). Also, levels of 
Salmonella in ileocecal lymph node and rectum content were slightly reduced but not 
significantly. However, Salmonella in other tissues, such as blood, lung, liver, and spleen 
was not quantitatively detectable. Meanwhile, Salmonella levels in cecal content in the 
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pigs of phage treatment group were 2.2 logs lower than those of Salmonella positive control 
(Table 10). The levels observed in the cecal contents in this animal trial were also 
approximately 1.5 logs lower than those of Experiment 5. However, the levels of 
Salmonella in gut contents in the pigs of phage-treated group still remained between 3.84 to 
4. 72 logs (Table 10). 
Animal trial 2 
With a shorter time between Salmonella challenge and necropsy as compared to 
animal trial 1 above, phage administration significantly reduced the levels of Salmonella in 
tonsils (P < 0.05), colon contents (P < 0.01), and cecal contents (P < 0.05) in the pigs of the 
phage-treated group (Table 11). Salmonella levels in ilea! and rectal contents were slightly, 
though not significantly, reduced by phage administration. In other tissues, Salmonella 
levels were not quantitatively detectable. The remaining levels of Salmonella in tissues 
observed in this trial were similar to those of animal trial 1 (Table 10). 
Animal trial 3 
Salmonella levels in the tissues were slightly reduced by phage administration 
within 3 hours between initial Salmonella challenge and the necropsy point (Table 12). 
Even though considerable numbers of Salmonella were reduced by phage administration, 
no statistical significance was found between tissues of the phage-treated group and 
Salmonella positive control group. 
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Experiment 7: Comparison of the effectiveness of F0-1 phage in reducing 
Salmonella serovar Typhimurium levels in pigs by different 
administration routes 
Reduction of Salmonella 
In animal trial 1 (Table 13), phage administration via oral route significantly 
reduced Salmonella levels in cecal and colon contents in the phage-treated group compared 
to those of the untreated control group (P< 0.01). On the contrary, phage administration via 
IM+ oral route only slightly reduced the level of Salmonella in tonsil, cecal, and colon 
contents. Meanwhile, in the case of animal trial 2 (Table 14), IM+ oral administration of 
phage lysate significantly reduced the levels of Salmonella in cecal content (P < 0.05) but 
not other tissues. 
Qualitative results 
With qualitative analysis of Salmonella levels in some tissues in both cases of the 
animal trial 1 and 2, no significant differences in Salmonella levels in between the tissues of 
the Salmonella-positive control group and phage-treated group in either animal trial (Table 
13, 14). 
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Table 1. Location and source of samples submitted for phage isolation 
Phage strain Source Sample type 
HL-02 human waste treatment plant, Ames. IA raw sewage(< 1 % solid) 
HL-03 human waste treatment plant, Ames. IA raw sewage(< 3-5% solid) 
HL-04 human waste treatment plant, Ames. IA digestion(95°F, 4-6% solid) 
HL-05 Clyde Black and son's pig farm, Sheldahl. IA farrowing unit - gutter 
HL-06 Clyde Black and son's pig farm, Sheldahl. IA growing unit - pit 
HL-07 I.S .U. teaching farm. Ames. IA south lagoon 
HL-08 I.S .U. teaching farm. Ames. IA south lagoon 
HL-09 I.S.U. teaching farm. Ames. IA north lagoon 
HL-10 Trettin Farm, Rockwell. IA lagoon of old nursery 
HL-11 BF Limited Farm, Ogden, IA north lagoon 
HL-12 BF Limited Farm, Ogden, IA north lagoon 
HL-13 BF Limited Farm, Ogden, IA north lagoon out of flow pipe 
HL-14 BF Limited Farm, Ogden, IA sludge of north lagoon 
HL-15 BF Limited Farm, Ogden, IA sludge of south lagoon 
HL-17 Calumet Gestation Barn, Pipestone, MN pit 1 
HL-18 Calumet Gestation Barn, Pipestone, MN pit 2 
HL-19 Calumet Gestation Barn, Pipestone, MN pit 3 
HL-20 Dogwood Ridge, Allen Co. KY. waste trough at farrowing 
HL-21 Dogwood Ridge, Allen Co. KY. gestation -pit 
HL-22 Dogwood Ridge, Allen Co. KY. lagoon 
HL-23 Bluestem, Scott's Bluff. NE finisher A -pit 
HL-24 Bluestem, Scott's Bluff. NE finisher B - pit 
HL-25 Bluestem, Scott's Bluff. NE lagoon 
HL-26 Bluegrass, Allen Co. KY waste trough 
HL-27 Bluegrass, Allen Co. KY finisher - pit 
HL-28 Bluegrass, Allen Co. KY lagoon 
HL-29 Squire Lyle, Allen Co. KY lagoon 
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Figure 2. A spot test to determine the lytic activity of phages to lawn-growth of Salmonella serovar 
Typhimurium on an LB agar plate 
The left circle (dotted lined) indicates that Salmonella serovar Typhimurium was not susceptible to 
an applied phage, whereas the right circle (clear spot) indicates that Salmonella serovar Typhimurium was 
susceptible to another applied phage. 
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Figure 3. Plaques of an isolated phage on an LB agar plate with lawn-growth of Salmonella serovar 
Typhimurium on an LB agar plate. 
Table 2. Host range of phages isolated from swine and human sewage samples across several serovars of Salmonella 
Serovar of Salmonella Isolated phages 
1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 1-Il., 
serogroup 02 03 04 05 06 07 08 09 10 11 12 13 14 
Salmonella serovar Typhimurium X 4232 B + + + + + + + + + + + + + 
Salmonella serovar Typhimurium variant B + + + + + + + + + + + + + 
Copenhagen 
Salmonella serovar Agona B + + + + + + + + + + + + + 
Salmonella serovar Bredeney B + + + + + + + + + + + + + 
Salmonella serovar Brandenburg B + + + + + + + + + + + + + 
Salmonella serovar Derby B + + + + + + + + + + + + + 
Salmonella serovar Mbandaka Cl + + + + + + + + + + + + + 
Salmonella serovar Thompson Cl + + + + - - + + - - + + -
Salmonella serovar Infantis Cl - + + + - - - - - - + - + 
Salmonella serovar Orenburg Cl - + - + - - - - - + - - -
Salmonella serovar Choleraesuis variant Cl - + + - - - - - - - - - -
Kunzendorf 
Salmonella serovar Choleraesuis Cl - + + - - - - + - - + - -
Salmonella serovar Newport C2 - + - + - - - - - - + - + 
Salmonella serovar Munchen C2 - + - + - - - - - - - - -
Salmonella serovar Heidelberg Dl + + + + + + + + + + + + + 
Salmonella serovar Enteritidis Dl + + + + + + + + + + + + + 
Salmonella serovar Javina Dl + + + + + + + + + + + + + 
Salmonella serovar Anatum El - + - + - - - - - - + - + 
Salmonella serovar Worthington G2 - - + - - - - - - - - - -
Table 2 (continued) 
Serotype of Salmonella Isolated phages 
HL HL HL HL HL HL HL HL HL HL HL HL HL serogroup 
15 17 18 19 20 21 22 23 24 26 27 28 29 
Salmonella serovar Typhimuriumx 4232 B + + + + + + + + + + + + + 
Salmonella serovar Typhimurium variant B + + + + + + + + + + + + + Copenhagen 
Salmonella serovar Agona B + + + + + + + + + + + + + 
Salmonella serovar Brendeney B + + + + + + + + + + + + + 
Salmonella serovar Brandenburg B + + + + + + + + + + + + + 
Salmonella serovar Derby B + + + + + + + + + + + + + 
Salmonella serovar Mbandaka Cl + + + + + + + + + + - - + 
Salmonella serovar Thompson Cl + - + + + + + + + + + + + 
Salmonella serovar Infantis Cl - - + + + + + + - - - + + 
Salmonella serovar Orenburg Cl - - + - + + - + - - - - + 
Salmonella serovar Choleraesuis variant Cl - - - - - - - - - - - -+ Kunzendorf 
Salmonella serovar Choleraesuis Cl - - + + + - + - - - - + -
Salmonella serovar Newport C2 - - + - + + - + - - - - + 
Salmonella serovar Munchen C2 - - + - - + - + - - - - -
Salmonella serovar Heidelberg Dl + + + + + + + + + + + + + 
Salmonella serovar Enteritidis Dl + + + + + + + + + + + + + 
Salmonella serovar Javina Dl + + + + + + + + + + + + + 
Salmonella serovar Anatum El - - + - - + - + - - - - + 
Salmonella serovar Worthington G2 - - - - - - - - - - - - -
Table 3. The average number of Salmonella serovar Typhimurium in fecal samples in pigs that were challenged with Salmonella and treated with a 
phage cocktail (Experiment 2) 
Events 
Assigned group 
D+l8hrs D+42hrs D+66hrs D+0hr (Immediately before (24hrs after phage ( 48hrs after phage (Salmonella challenge) phage cocktail treatment) cocktail treatment) cocktail treatment) 
Salmonella positive control 
(phage cocktail - untreated) o· 5.70±0.43 3.20±1.05 4.06±0.40 
Phage cocktail - treatment 
(via intraperitoneal route) 0 4.56±1.16 4.17±0.56 5.15±0.11 
Phage cocktail - treatment 
(via intramuscular route) 0 3.22±0.75 2.52±0.73 2.35±0.77 
Phage cocktail - treatment 
(via oral treatment) 0 3.04±0.87 3.01±1.03 3.07±1.00 
•The numbers indicate the average± standard error of the logarithmic values obtained from 2 pig (D+42hrs), and 3 pigs (D+66hrs) within each group, and 
represent the colony forming unit (CFU) /gram of fecal samples .. 
Table 4. The average number of Salmonella serovar Typhimurium in tissue samples of 2 pigs sacrificed at 24 hours after administration of a phage cocktail 
(Experiment 2) 
Group 
(N = 2 pigs) 
Salmonella positive control 
(phage cocktail - untreated) 
Phage cocktail - treatment 
(via intraperitoneal route) 
Phage cocktail - treatment 
(via intramuscular route) 
Phage cocktail - treatment 
(via oral treatment) 
a: mesenteric lymph node 
b: not tested 
Blood Liver Spleen Lung 
NTb NT NT NT 
NT NT NT NT 
NT NT NT NT 
NT NT NT NT 
c: not detectable (less than log102 was undetectable by the method used in the present study) 
Tonsil Ileum MLNa Cecum 
NDC 2.14±2.14 4.06±0.26 4.19±0.00 
2.58±2.56 4.08±0.88 1.00±1.00 4.98±0.00 
2.29±0.99 3.73±0.23 4.33±0.05 3.89±1.11 
2.00±0.42 1.50±0.20 3.79±1.00 2.45±2.45 
Table 5. The number of Salmonella serovar Typhimurium in tissue samples of 3 pigs sacrificed at 48 hours after administration of a phage cocktail 
(Experiment 2) 
Group 
(N = 2 pigs) 
Salmonella positive control 
(phage-untreated) 
Phage-treatment 
(via intraperitoneal route) 
Phage-treatment 
(via intramuscular route) 
Phage-treatment 
(via oral treatment) 
a: mesenteric lymph node 
b: not tested 
Blood 
NTb 
NT 
NT 
NT 
Liver Spleen Lung 
NT NT NT 
NT NT NT 
NT NT NT 
NT NT NT 
c: not detectable (less than logl02 was undetectable by the method used in the present study) 
Tonsil Ileum MLN• Cecum 
1.58±1.58 NOC 3.95±0.20 2.61±1.31 
2.68±1.33 ND 3.79±0.22 3.91±0.64 
3.89±1.82 1.23±1.75 1.18±1.18 2.93±0.04 
3.75±1.02 0.96±1.67 3.75±0.50 3.58±0.79 
Table 6. Host range ofF0-1 phage against various serovars of Salmonella (Experiment 3) 
Serovar of Salmonella 
Salmonella serovar Typhimurium x 4232 
Salmonella serovar Typhimurium variant Copenhagen DT 104(00-22180) 
Salmonella serovar Agona HL10107 
Salmonella serovar Brendeney HL10024 
Salmonella serovar Brandenburg (FY200 ACC58748) 
Salmonella serovar Derby HL 10117 
Salmonella serovar Mbandaka (00-16757) 
Salmonella serovar Thompson HL10189 
Salmonella serovar Montevideo (FY2000 ACC 56805) 
Salmonella serovar Infantis HL10814 
Salmonella serovar Oranienburg (FY2000 ACC 58058) 
Salmonella serovar Choleraesuis variant Kunzendorf (00-21568) 
Salmonella serovar Choleraesuis DK143 (HL 10808) 
Salmonella serovar Newport HL10349 
Salmonella serovar Munchen HL10009 
Salmonella serovar Heidelberg HL10054 
Salmonella serovar Enteritidis (FY2000 200-55808) 
Salmonella serovar Javina (FY2000 ACC 37532) 
Salmonella serovar Anatum (00-14489) 
Salmonella serovar Worthington HL10049 
+: lysis within spot area 
_: no lysis within spot area 
a: United States Department of Agriculture 
b: National Veterinary Service Laboratory 
c: refer to the cited reference 
Serogroup 
B 
B 
B 
B 
B 
B 
C1 
C1 
C1 
C1 
C1 
C1 
C1 
C2 
C2 
D1 
D1 
D1 
E1 
G2 
Source Susceptibility to F0-1 phage 
USDA + 
NVSL0 + 
(47)° + 
(47) + 
NVSL + 
(47) + 
NVSL + 
(47) + 
NVSL + 
(47) + 
NVSL + 
NVSL + 
(47) + 
(47) + 
(47) + 
(47) + 
NVSL + 
NVSL + 
NVSL + 
(47) -
Table 7. Lytic activity ofF0-1 phage to multi-drug resistant Salmonella serovar Typhimurium (Experiment 3) 
Serovar of Salmonella 
Salmonella serovar Typhimurium 00-22180 
Salmonella serovar Typhimurium E96-l 790 TM75 
Salmonella serovar Typhimurium E97-698 TM 123 
Salmonella serovar Typhimurium E97-1233 TM 56 
Salmonella serovar Typhimurium DHEP 12352 
Salmonella serovar Typhimurium 13 HP 
Salmonella serovar Typhimurium F 515-95 
a: National Veterinary Service Laboratory 
b: Minnesota Department of Health 
c: Center for Disease Control and Prevention 
Sources Antibiogramd 
NVSL" ACSSuTTcPiAcSp 
MDHb ACSSuTTcPiAcSp 
MDH ACSSuTTcPiAcSp 
MDH ACSSuTTcPiAcSp 
CDC' ACSSuTTcPiAcSp 
CDC ACSSuTTcPiAcSp 
CDC ACSSuTTcPiAcSp 
Susceptibility to F0-1 phagee 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
d: A: Ampicillin, C: Chloramphenicol, S: Streptomycin, Su: Sulfonamide, T: Tetracycline, Tc: Ticarcillin, Pi: Piperacillin, Ac: Amoxilcillin, Sp: 
Spectinomycin. 
e: +: lysis within spot area,-: no lysis within spot area 
Table 8. The number of Salmonella-culture positive tissue samples in pigs that were sacrificed at 3 hours after Salmonella serovar Typhimurium challenge 
via intranasal route (Experiment 4) 
Tissues 
Salmonella challenged dose 
blood tonsil liver spleen lung ICLNa 
cecum rectum 
lxl08 CFU 
(N=3) 0/3 2/3 2/3 2/3 0/3 2/3 3/3 1/3 
lxl05 CFU 
(N=3) 0/3 3/3 0/3 0/3 0/3 1/3 2/3 0/3 
no challenge 
(N=2) 0/2 0/2 0/2 0/2 0/2 0/2 0/2 0/2 
a: ileocecal lymph node 
Table 9. The number of Salmonella serovar Typhimurium in tissues of pigs that were treated at 3 hours with a single dose ofF0-1 phage preparation and 
sacrificed at 9 hours after Salmonella challenge (Experiment 5) 
Average numbers of Salmonella (log10 No.lg of sample) 
Samples P values 
positive control phage treatment group 
(N=5) (N=5) 
Tonsil 5.68±0.68 2.00±0.0 <0.01 
ICLN" 2.89±0.51 2.24±0.23 0.41 
Cecum 7.12±0.09 5.26±0.34 < 0.01 
Rectum NDb ND 
Lung ND ND 
Spleen ND ND 
Liver ND ND 
": ileocecal lymph node 
b: not detectable (detection limit was log102 CFU/g of sample) 
V, 
0 
Table 10. The number of Salmonella serovar Typhimurium in tissues of pigs that received F0-1 phage preparation intermittently and were sacrificed at 12 
hours after Salmonella challenge (Experiment 6, Animal Trial 1) 
Average numbers of Salmonella (log10 No./gram of sample) 
Samples P values 
positive control phage treatment group 
(N=5) (N=5) 
Tonsil 6.51±0.21 4.54±0.35 <0.01 
ICLN" 2.67±0.48 1.63±0.32 0.10 
Colon 5.84±0.19 4.08±0.44 <0.01 
Cecum 6.09±0.14 3.84±0.45 <0.01 
Rectum 5.95±0.47 4.72±0.47 0.14 
Blood NDb ND -
Lung ND ND -
Liver ND ND 
-
Spleen ND ND 
-
a: ileocecal lymph node 
b: not detectable (detection limit was log 101 CFU/g of sample) 
U\ 
-
Table 11. The number of Salmonella serovar Typhimurium in tissues of pigs that received F0-1 phage preparation intermittently and were sacrificed at 5 
hours after Salmonella challenge (Experiment 6, Animal Trial 2) 
Samples Average numbers of Salmonella (log10 No./gram of sample) 
positive control phage treatment group P values 
(N=5) (N=5) 
Tonsil 3.98±0.28 2.89±0.39 <0.05 
Ileum 5.91±0.23 3.58±1.17 0.06 
Colon 7.13±0.41 4.73±0.49 <0.01 
Cecum 6.56±0.58 4.67±0.54 <0.05 
Rectum 6.12±0.57 4.46±0.36 0.06 
ICLN" NDb ND -
Blood ND ND -
Lung ND ND -
Liver ND ND -
Spleen ND ND -
a: ileocecal lymph node 
b: not detectable (detection limit was log101 CFU/g of sample) 
Vt 
N 
Table 12. The number of Salmonella serovar Typhimurium in tissues of pigs that received F0-1 phage preparation intermittently and were sacrificed at 3 
hours after Salmonella challenge (Experiment 6, Animal Trial 3) 
Average numbers of Salmonella (log10 No. /g of sample) 
Samples P values 
positive control phage treatment 
(N=4) (N=5) 
Tonsil 3.74±0.18 3.78±0.12 0.87 
Cecum 6.00±0.69 3.64±0.98 0.10 
Colon 4.28±1.16 1.96±0.4 0.10 
Blood ND" ND -
Lung ND ND -
Spleen ND ND -
Liver ND ND -
a: not detectable (detection limit was log101 CFU/g of sample) 
Table 13. The number of Salmonella serovar Typhimurium in tissues of pigs that received F0-1 phage preparation intermittently and were sacrificed at 12 
hours after Salmonella challenge (Experiment 7, Animal Trial) 
Table 13. The number of Salmonella serovar Typhimurium in tissues of pigs that received F0-1 phage preparation intermittently and were sacrificed at 12 
hours after Salmonella challenge (Experiment 7, Animal Trial) 
Average numbers of Salmonella (log10 No. /g of sample) 
Samples 
positive control phage treatment phage treatment 
(N=4) (via IM+ oral route) ( via oral route) 
Tonsil 4.41±0.12 4.27±0.09 3.87±0.37 
Cecum 6.59±0.16 5.47±0.48 3.68±0.47 .. 
Colon 6.05±0.51 4.61±0.48 1.70±0.73** 
qualitative levels of Salmonella in tissues (No. of positive /No. of total samples) 
Mandibular lymph node 4/5 515 5/5 
Liver 1/5 2/5 5/5 
Spleen 3/5 2/5 5/5 
Ileoceal lymph node 5/5 2/5 3/5 
**: P < 0.01 
Table 14. The number of Salmonella serovar Typhimurium in tissues of pigs that received F0-1 phage preparation intermittently and were sacrificed at 12 
hours after Salmonella challenge (Experiment 7, Animal Trial) 
Average numbers of Salmonella (log10 No. lg of sample) 
Samples 
positive control phage treatment phage treatment 
(N=4) (via IM+ oral route) (via oral route) 
Tonsil 5.06±0.23 4.22±0.28 4.58±0.31 
Cecum 6.16±0.44 4.58±0.46* 5.21±0.21 
Colon 5.29±0.82 3.97±0.40 3.89±0.47 
qualitative levels of Salmonella in tissues (No. of positive /No. of total samples) 
Mandibular lymph node 5/5 5/5 5/5 
Liver 3/5 3/5 0/5 
Spleen 3/5 2/5 2/5 
Ileocecal lymph node 4/5 3/5 2/5 
*: P < 0.05 
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CHAPTER 5. DISCUSSION 
In order to evaluate the potential of phages as a possible intervention strategy 
against Salmonella spp. in pigs, the present study was conducted with two different 
approaches: one was to use a mixture of phages, or a "phage cocktail", and the other was to 
use a single broad-host range Salmonella phage, F0-1. These approaches were based on the 
recommendations observed in relatively recent studies that tried to improve the 
effectiveness of phage treatment (95, 145). 
As the initial step to address the first approach, phages capable of lysing several 
serovars of Salmonella were isolated from sewage samples (Table 1). With an in vitro 
assay, all isolated phages lysed serogroup B and D 1• Salmonella serovar Typhimurium, the 
organism used to isolate these phages, belong to serogroup B and has an antigenic factor in 
common with serogroup D1 (16). However, most isolated phages, except phages HL03 and 
HL18, had a relatively narrow range of lytic activity against serovars of Salmonella, which 
appeared to be serogroup-specific (Table 2). Interestingly, these 2 phages were able to lyse 
more serovars of Salmonella than other phages (Table 2). The reason for the broad lytic 
activity of these phages has not been further characterized in the present study. 
The narrow lytic activity observed in most isolated phages was not surprising 
because the specificity of phage to target bacteria has been well described as a general 
property of phages (1 , 3). The specificity of Salmonella phage are due to a difference in the 
affinity of interaction between the tips of the tail fibers of the phage and receptor molecules 
located on the outer membrane of Salmonella (16, 25, 104, 106). In general, a single 
smooth-type phage with a narrow specificity cannot lyse many strains of bacteria of the 
same genus because many others will lack the receptor molecules for the phage (73, 95, 
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122). This property of phages has been described as one of the major obstacles to the use 
of phages therapeutically in vivo (32, 152). This issue seems to be a particularly serious 
matter in the use of phage against Salmonella spp. because of its antigenic diversity. 
Accordingly, when a single isolated phage is used for Salmonella spp., the spectrum of lytic 
ability of the phage should be determined before application into animals. 
The goal of the first approach was to gain insight into the feasibility of the use of a 
phage cocktail to either reduce the levels of Salmonella or eliminate Salmonella entirely in 
pigs. Phage cocktails consisting of the isolated phages were administered to the Salmonella 
infected pigs via different routes. The results observed in this trial showed no statistical 
difference in the levels of Salmonella in tissues of the pigs between a phage-treated group 
and an untreated control group, regardless of administration route (Table 3, 4, and 5). 
Unfortunately, some tissues isolated from pigs in the phage-treated group showed higher 
levels of Salmonella as compared to those of control group (Table 3, 4, and 5). This was 
quite surprising because the phage cocktails were made to broaden the spectrum of lytic 
activity of phages (90, 95). The expected result would have been a synergistic effect of each 
different phages against the Salmonella infection (15, 90, 95, 145) 
The results observed in this trial indicated a trend in reducing the level of Salmonella 
by administration route of the phage cocktail (Table 4 and 5). The degree of Salmonella 
reduction in tissues was dependent on the administration route and the length of time 
between phage treatment and the sampling point. In the mesenteric lymph node (MLN), a 
considerable reduction of Salmonella was seen with intraperitoneal (IP) administration of 
phage post 24 hours phage treatment but not post 48 hours (Table 4 and 5). A reasonable 
interpretation of this may by that phage particles given via IP route are likely to be taken up 
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by the lymphatic system in the peritoneal cavity and to affect the levels of resident 
Salmonella in the MLN for only 24 hours post phage treatment. In contrast, the levels of 
Salmonella were slightly reduced in the MLN when the phage cocktail was administered 
via intramuscular (IM) routes 48 hours post phage treatment, but not 24 hours. This might 
have occurred because phage particles given via the IM route needed more time (48, not 24 
hours) to circulate into the MLN, and thus affect the levels of Salmonella present (Table 4 
and 5). Also, oral administration of the phage cocktail reduced the levels of Salmonella in 
the gut contents 24 hours post phage treatment rather than 48 hours. The trend in reducing 
Salmonella observed in this trial may be supported by a study of phage particles in mice. 
This study showed a correlation between tissue concentrations and injection routes of phage 
particles (59). Other studies have illustrated that application of a phage cocktail was 
effective in reducing the numbers of Salmonella in chickens (145) and in clearing E. coli 
0157 in vitro (90). These studies also suggested that utilization of the phage cocktail could 
overcome the problem associated with phage specificity. 
The results observed in this trial may not adequately represent the effectiveness of the 
phage cocktail because the results were obtained from a single animal trial with a relatively 
small number of pigs. However, no significant reduction of Salmonella by application of 
the phage cocktail was observed. Taken together, the effectiveness of phage treatment may 
not be related to the use of the phage cocktail. The efficacy of phage therapy may also be 
affected by factors other than lytic activity, such as the genetic and/or physiological 
properties of Salmonella and phage. For example, in phage cocktails consisting of several 
phages, the original formula of phage cocktail would not be maintained in vivo because 
each phage produces its own number of progeny upon multiplication in the host. This 
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could result in a change in the concentration of the various phages in the cocktail. This 
suggests that the use of the phage cocktail may not be as effective as a single broad-host 
range phage. 
In light of these results, a second approach was carried out to search for a single 
phage that is capable of lysing a broad range of Salmonella. An in vitro assay showed that 
F0-1 phage effectively lysed the serovars of Salmonella most frequently found on swine 
farms (Table 6) and multi-drug resistant strains of Salmonella serovar Typhimurium (Table 
7), consistent with previous studies (61, 85-87). It was found that F0-1 phage can adsorb 
on a common component on the core region of lipopolysaccharide on the outer membrane 
that is shared among most Salmonella (70, 105, 175). Few mutants of Salmonella are able 
to resist F0-1 phage because of the stability of the phage receptor component on the 
bacterial LPS structure (20, 147). Before further animal trials, an acute Salmonella 
infection model in pigs was established (Experiment 4) in order to more closely mimic the 
lairage situation immediately prior to slaughter. Salmonella serovar Typhimurium, (even in 
at low infectious dose), can spread into tissues within 3 hours after an initial challenge via 
intranasal route (Table 8), which agreed with previous studies (51, 74, 75). The rate of 
Salmonella -positive tissues 3 hours post challenge was somewhat dependent on infectious 
dose (Table 8). Unlike other tissues, there was a constant presence of Salmonella on tonsil 
between both groups. Perhaps, the intranasally inoculated Salmonella existed on the 
superficial surface or crypts of tonsils for a short period of time (as 3 hours) rather than a 
true invasion into deep location of the tonsils . In addition, statistically significant 
differences in the rate of Salmonella -positive tissues between two different inoculation 
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doses were not found (P=0.07). This model was used for the next animal trials in order to 
study the type of Salmonella infection that may occur in market hogs before slaughter. 
In this animal model, a single administration of F0-1 phage lysate via both IM and 
oral routes 3 hours post Salmonella challenge significantly reduced the levels of Salmonella 
in tonsil and cecal content, but only slightly reduced bacteria in ileocecal lymph node 
(ICLN) (Table 9). The levels of Salmonella in other tissues were below the detection 
ability of the method described. Meanwhile, considerable numbers of Salmonella (5.26 
logs) remained in the cecal content in the phage-treated pigs. These seemed high compared 
to the contents in pigs Salmonella naturally infected, whose levels are likely enough to 
infect other animals before slaughter (74). Further investigation was necessary for lowering 
the remaining numbers of Salmonella by phage administration. 
With this in mind, further animal trials were conducted to search for optimal 
conditions to improve the effectiveness of F0-1 phage administration. We examined 
several aspects, including changing the amounts of phage lysate administrated into the 
Salmonella infected pigs, changing the period of time between an initial challenge and a 
sacrifice point, and varying the administration routes of phage lysate. This was based on 
the idea that increasing the volume of phage lysate administrated into the pigs will increase 
the numbers of phage particles in the gut contents, which may result in improved 
effectiveness of the phage for reducing the levels of Salmonella. Also, an extended time 
between initial phage administration and a necropsy point could help in moving phage 
particles to the distal part of the intestinal tract of the pigs (92), in order to improve the 
effectiveness of phage treatment in colon and cecal contents. Additionally, the period of 
time between Salmonella challenge and initial phage treatment was shortened because some 
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studies suggested that the efficacy of phage treatment was better when the period was 
shorter or simultaneous (12, 73, 147). 
Based on this idea, the phage lysate was intermittently administered to Salmonella 
infected pigs which were sacrificed 12 hours post challenge (Experiment 6, Animal Trial 1). 
This also led to modification of administration route by trying to add the phage preparation 
into the drinking water for the pigs to be accessed before slaughter. In combination with 
the extended time to necropsy from the initial phage treatment, the increased volume of 
phage preparation administered into pigs appeared to improve the degree of Salmonella 
reduction in cecal contents as compared to those that received a single application of phage 
lysate (Table 9 and 10). On the other hand, with a shorter period of time between 
Salmonella challenge and necropsy (Experiment 6, Animal Trial 2), the results obtained 
were similar to those of the animal trial where the phage lysate was administered multiple 
times (Experiment 6, Animal Trial 1). In another trial with a much shorter duration 
between Salmonella challenge and necropsy (Experiment 6, Animal Trial 3), Salmonella 
levels in the cecal and colon contents were considerably reduced by the phage treatment as 
compared to the phage-untreated control group (Table 12). However, these results were not 
statistically significant because of a high variation of the numbers of Salmonella present in 
the tissues. Despite changing the conditions, no significant difference was found between 
the trials conducted in Experiment 6. These trials could not support the hypothesis that the 
increased volume of phage preparation would better reduce the Salmonella levels in the 
tissues of phage-treated pigs. 
Another experiment was performed to determine which administration route was 
most effective in reducing the Salmonella levels in pigs (Experiment 7). Salmonella levels 
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were consistently reduced in tonsil, cecal and colon contents by either oral route or IM and 
oral routes (Table 13 and 14). However, the results observed in replicate studies did not 
demonstrate which route was better in reducing the levels of Salmonella. The qualitative 
analysis of Salmonella in MLN, ICLN, spleen and liver, showed no statistically significant 
reduction in the rate of Salmonella-positive tissue following phage administration, 
indicating that phage treatment does not eliminate the microorganism from the phage-
treated animals. 
Meanwhile, the acute transmission of drug-resistant Salmonella in food animals 
immediately prior to slaughter seems to be uncontrollable by current available commercial 
means. To address this problem, a few studies using phages were recently performed (20, 
73, 120, 145). Unfortunately, the effectiveness of phage treatment for reducing the levels 
of bacteria in animals was similar whether phages were used therapeutically or as an 
intervention tool (20, 145). As was presented here, these studies found that phage treatment 
consistently reduced the Salmonella levels in pigs but a considerable number of 
microorganisms remained in the gut contents. These remaining Salmonella levels were 
quite similar to those of other animals observed in previous studies (20, 145). Moreover, 
there was no report that phage treatment was able to completely eliminate the target 
bacteria in the gut contents in phage-treated animals. Recently, Payne et al suggested a 
mathematical model to understand the unpredictable outcome observed in earlier studies of 
phage therapy (133). According to the model, when targeted bacterial levels are over the 
"critical threshold", which is the minimal numbers of bacteria required for phage 
multiplication in vivo, the amount of applied phages can reduce bacteria. The reduction is 
only effective to the critical threshold, but cannot lessen the numbers of bacteria when they 
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fall below the critical threshold mark (133, 134, 174). Eventually, the phages cannot 
effectively find or lyse the bacteria, and thus die off before all the bacteria are destroyed in 
vivo. On the other hand, Wiggins and Alexander also suggested that phages do not affect 
the number or activity of bacteria in the environment where the density of susceptible 
bacteria is below a "threshold" of about 104 CFU/ml (174). In combination, these ideas 
attempt to explain the unpredictable outcome of phage therapy and why a number of target 
bacteria remain in the gut contents of phage treated animals. Phage treatment may reduce 
the levels of target bacteria down to the critical threshold mark. Accordingly the number of 
bacteria remaining in the gut contents of phage-treated animals would be considered as a 
limit in utilizing phages for therapeutic intervention. Also, the studies presented here 
demonstrate a similar trend in reducing Salmonella by phage treatment. We are currently 
investigating the criteria for the optimal conditions for effective phage application in 
reducing the levels of drug resistant strains of Salmonella in swine naturally infected with a 
low bacterial dose in the environment (118, 156) 
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CHAPTER 6. CONCLUSIONS 
Salmonella infection in swine prior to slaughter is a significant risk factor to pork 
quality, with the eventual possibility of foodborne illnesses in consumers (21, 158). 
Realistically, transmission of Salmonella prior to slaughter seems to be uncontrollable by 
available commercial means (158). In this study, we evaluated the feasibility of using 
phages against Salmonella. First, phages capable of lysing several serovars of Salmonella 
were isolated from sewage samples and used for a "phage cocktail". Administration of the 
phage cocktail was not effective in reducing Salmonella levels in pigs. Secondly, through 
an in vitro assay, a single Salmonella F0-l phage was chosen for further studies because the 
phage was able to lyse a broad range of Salmonella serovars. In the acute Salmonella 
infection model of pigs, the effectiveness of F0-1 phage for reducing Salmonella levels was 
determined with several experimental designs. Administration of F0-1 phage consistently 
reduced the levels of Salmonella throughout all animal trials in the present study. The 
degree of reduction was between 1.0 log and 4.0 logs, which was relatively similar in all 
cases regardless of differing conditions. Considerable numbers of Salmonella remained in 
the gut contents of phage-treated pigs, indicating a limit for phage treatment as a practical 
intervention method. 
Nevertheless, the results presented here demonstrate that a phage-based intervention 
strategy could be a possible approach for reducing Salmonella levels of acutely infected 
pigs if its efficacy is improved. The optimal conditions for utilizing phage to reduce 
Salmonella in swine should be ascertained by determining the efficacy of phage treatment 
in preventing the natural transmission of Salmonella in swine and determining the 
minimum concentration of phage particles able to effectively reduce the levels of 
Salmonella in swine. 
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